Forbion's third Growth Opportunities vehicle supplies expansion capital to later-stage life-sciences companies approaching major clinical and commercial milestones. Its final close was reported at €1.2bn on 15 Oct 2024. The mandate covers Europe and North America. The stated stage focus is Growth and Late Stage, with emphasis on Biotech and Health & Life Sciences.
At a glance
Related tracked funds
Source and review
This fund record was manually reviewed on by the EverythingVC editorial team under our research methodology.
The capital figure reflects commitments reported by the cited source. It is not an estimate of remaining dry powder or current fundraising availability.
- Fund announcement: Forbion fund announcement